. 11. Complementary DNAs encoding the short forms of G␣ s WT and G␣ s * (9) were subcloned into pUAST (7) and used to transform flies [A. Spradling, in Drosophila: A Practical Approach, D. Roberts, Ed. (IRL Press, Oxford, 1986), pp. 75 -197]. The UAS-G␣ s lines were verified by Msc I digestion of polymerase chain reaction-amplified G␣ s transgenes to detect the presence of a site found in G␣ s WT but lacking as a result of the Q215L mutation. 12. 238Y and 201Y are described in (17) and C232 in (18). C747 shows identical expression to that of C772 (17) (24). C309 is described by J. D. Armstrong [thesis, University of Glasgow, Scotland (1995)]. The O'Kane laboratory screened 500 P-GAL4 lines to identify OK66, OK86, OK62, OK107, OK348, and OK415. 13. T. Tully and W. Quinn, J. Comp. Physiol. 157, 263 (1985); T. Tully, T. Preat, S. Boynton, M. Del Vecchio, Cell 79, 35 (1994). 14. In total, we analyzed behaviorally 16 P-GAL4 insertions that expressed to some degree in MBs. Flies with four insertions (OK66, OK86, KL65, and KL107) showed reduced learning in the absence of expression of constitutively activated G␣ s *, most likely because of genetic background differences. These were not tested further. Flies with eight insertions showed defects in olfactory acuity (30Y, C35, OK62, OK107, C302, OK415, and C532) or shock reactivity (C772), as transheterozygotes with UAS-G␣ s *. These were eliminated from further behavioral testing. Flies with the remaining four P-GAL4 insertions (201Y, 238Y, C309, and C747) showed disrupted learning but normal olfactory acuity and shock reactivity, as transheterozygotes with at least one UAS-G␣ s * insertion. We characterized a total of two P-GAL4 insertions (C232 and OK348) that expressed to some degree in the CC. 15. We suggest that olfactory learning results from G sdependent convergence of the conditional stimulus (CS) and unconditional stimulus (US) in the MBs. This belief is reinforced by the observation that expression of G␣ s * in the CC does not affect learning. 
The UAS-G␣ s lines were verified by Msc I digestion of polymerase chain reaction-amplified G␣ s transgenes to detect the presence of a site found in G␣ s WT but lacking as a result of the Q215L mutation. 12. 238Y and 201Y are described in (17) and C232 in (18) . C747 shows identical expression to that of C772 (17) (24). C309 is described by J. D. Armstrong [thesis, University of Glasgow, Scotland (1995) ]. The O'Kane laboratory screened 500 P-GAL4 lines to identify OK66, OK86, OK62, OK107, OK348, and OK415. 13. T. Tully and W. Quinn, J. Comp. Physiol. 157, 263 (1985) ; T. Tully, T. Preat, S. Boynton, M. Del Vecchio, Cell 79, 35 (1994). 14. In total, we analyzed behaviorally 16 P-GAL4 insertions that expressed to some degree in MBs. Flies with four insertions (OK66, OK86, KL65, and KL107) showed reduced learning in the absence of expression of constitutively activated G␣ s *, most likely because of genetic background differences. These were not tested further. Flies with eight insertions showed defects in olfactory acuity (30Y, C35, OK62, OK107, C302, OK415, and C532) or shock reactivity (C772), as transheterozygotes with UAS-G␣ s *. These were eliminated from further behavioral testing. Flies with the remaining four P-GAL4 insertions (201Y, 238Y, C309, and C747) showed disrupted learning but normal olfactory acuity and shock reactivity, as transheterozygotes with at least one UAS-G␣ s * insertion. We characterized a total of two P-GAL4 insertions (C232 and OK348) that expressed to some degree in the CC. 15 ) is required for diazaborine binding; this finding has led to the suggestion that the drug binds to ENR in association with NAD ϩ or that NAD ϩ converts the drug to an active form (5) . To obtain a molecular explanation for the inhibitory activities of this class of antibacterial agents, we determined and analyzed the structure of E. coli ENR in complexes with NAD ϩ and either thienodiazaborine or benzodiazaborine as well as with NAD ϩ alone. The structure of the ENR-NAD ϩ complex was solved to 2.1 Å (6); those of the ENR-NAD ϩ -thienodiazaborine and ENR-NAD ϩ -benzodiazaborine complexes were solved to 2.2 and 2.5 Å, respectively (7) ( Table 1 and Fig. 1A ). In the final map of the ENR-NAD ϩ complex, the electron density is of high quality for most of the protein atoms. However, there is a break in the density for a stretch of 10 amino acid residues; these 10 residues form a loop, between strand ␤6 and helix ␣6, that borders the nucleotide-binding site. In the structures of the ENR-NAD ϩ -diazaborine complexes, this loop is well defined and provides two residues whose side chains are in van der Waals contact with the non-boroncontaining five-and six-membered rings of thienodiazaborine and benzodiazaborine, respectively.
The quality of the electron density map for both diazaborines enabled the unambiguous positioning of the bicyclic thienodiazaborine or benzodiazaborine rings, the sulfonyl groups, and the respective propyl or tosyl substituents (Fig. 1, B 2 ) and between a nitrogen in the boron-containing ring and an ordered solvent molecule.
Analysis of the drug complex showed that the distance between the boron atom of the diazaborine and the 2Ј hydroxyl of the nicotinamide ribose was ϳ1.7 Å, comparable with a B-O covalent bond length of 1.6 Å. The quality of the electron density map (particularly for the thienodiazaborine complex at 2.2 Å) implies that the errors in coordinates are very small, and thus we can be confident that the interaction between these two atoms is covalent. This conclusion is further supported by the unambiguous identification of the position of the hydroxyl oxygen to which the boron is linked, which can be seen to form part of a tetrahedral rather than a trigonal arrangement, as required if the boron forms four covalent bonds (Fig. 1, B and C) . This finding provides a clear explanation for the strong inhibitory properties of the diazaborines and for the requirement of NAD ϩ for diazaborine binding. The formation of the covalent bond further explains why the replacement of the B-N group in the diazaborine by an isoelectronic C-C unit in an isoquinoline analog showed no biological activity (8) . The formation of the covalent bond in this case resembles the manner in which the boronic acid inhibitors of serine proteases act through the chemical modification of the active-site serine to give a covalently bound tetrahedral adduct (9) .
The structure of the E. coli enzyme is closely related to that of its mycobacterial counterpart [Protein Data Bank (PDB) entry 1ENY (1); 40% sequence identity; 199 C␣ atoms superimposed, root-mean-square A C Fig. 1 . The E. coli ENR tetramer is made up of four subunits, each consisting of a single domain of approximate dimensions 55 by 45 by 45 Å composed of a parallel ␤ sheet of seven strands (␤1 to ␤7), flanked on one side by helices ␣1, ␣2, and ␣7 and on the other by helices ␣3 to ␣5, with a further helix, ␣6, lying along the top of the ␤ sheet. (A) Schematic diagram of a single subunit of the ENR-NAD ϩ -thienodiazaborine complex. The ribbon trace of E. coli ENR is shown in red; NAD ϩ (blue) and diazaborine (cyan) are shown in an all-atom representation. The loop that orders on diazaborine binding is highlighted in green. [Produced using MIDAS (25) .] (B and C) Initial Fourier maps of the NAD ϩ -thienodiazaborine complex at 2.2 Å resolution (B) and of the NAD ϩ -benzodiazaborine complex at 2.5 Å resolution (C) with the final refined structures superimposed. The density (contoured at 1.2 and 0.9, respectively) was calculated with coefficients 2͉F obs ͉ Ϫ ͉F calc ͉ and phases that were calculated from the refined structure from the molecular replacement solution that had been generated with the model of the E. coli ENR-NAD ϩ complex, which contained no information about the inhibitor. [Produced using BOBSCRIPT (26), a modified version of MOLSCRIPT (27) .] (D) The superposition (based on the nicotinamide and its associated ribose) of the nucleotide-inhibitor complex of ENR into the active site of the nucleotide-substrate complex of DHFR [PDB entry 7DFR (13)]. The C␣ backbone trace for DHFR is shown in green, with bound NADP and folate colored turquoise and by atom, respectively; the superimposed NAD ϩ and thienodiazaborine of ENR are shown in red and all atom colors, respectively (red, oxygen; white, carbon; blue, nitrogen; yellow, sulfur; green, boron). The covalent bond between the 2Ј hydroxyl of the nicotinamide ribose and the boron of the diazaborine in ENR is represented by a dotted yellow line. [Produced using MIDAS (25) .] When the NAD ϩ -thienodiazaborine complex is fitted into the active site of DHFR, there are some steric clashes between the sulfonyl group and the propyl tail of the diazaborine with parts of the enzyme surface. Nonetheless, there is sufficient space around the 2ЈOH of the nicotinamide ribose to envisage the formation of a linker between the ribose and a folate analog. 3 Ser (G93S) and Ser 94 3 Ala mutations, which lead to resistance to diazaborine (11) and isoniazid (1), respectively, map to regions close to the nucleotide-binding site. Modeling studies show that in the absence of changes to the main-chain torsion angles in the G93S mutant of E. coli ENR, the C␤ atom of the serine side chain would be unacceptably close to the two oxygens of the sulfonyl group of the diazaborine. Therefore, resistance to diazaborine is probably explained by the serine side chain of the G93S mutant encroaching into the drug-binding site and causing severe steric hindrance.
The position of the aromatic bicyclic ring of the diazaborine above the nicotinamide ring strongly resembles the model proposed for the binding of the enoyl substrate on the basis of studies on B. napus ENR (10), with the proposed position for the negatively charged oxygen of the enolate anion of the substrate close to that of the boron atom in the drug. Thus, the formation of a covalent bond between ENR and diazaborine generates a tight, noncovalently bound bisubstrate analog. No such good bisubstrate inhibitors have previously been described for NAD(P)-dependent oxidoreductases. Examples of this type designed to inhibit 3-hydroxy-3-methyl glutaryl (HMG) coenzyme A reductase were only very weak inhibitors of cholesterol biosynthesis, possibly because of the lack of a moiety to mimic the adenosine diphosphoribose, but more likely because of steric problems in the active site associated with the nature of the linkage that used the C-4 atom of the nicotinamide ring (12) . In contrast, our study provides clear evidence for the type of linkage that may need to be created in order to synthesize a bisubstrate analog with the necessary geometry to occupy the active-site cleft. This may prove crucial in the design of a new generation of antibacterial agents against a range of drug-resistant organisms, including M. tuberculosis. However, given the inherent toxic potential of boron (8) , the development of a range of inhibitors with minimal side effects will require the design of a preformed bisubstrate analog in which another atom is substituted for boron.
More widely, a number of NAD(P)-dependent oxidoreductases are known to be drug targets, including dihydrofolate reductase (DHFR), the target for the anticancer agent methotrexate (13) ; steroid 5␣-reductase, the target for finasteride, used to treat benign prostatic hyperplasia (14) ; and inosine monophosphate dehydrogenase (IMPDH), the target for the immunosuppressant mycophenolic acid (MPA) (15) . Structural analysis of members of the family of NAD(P)-dependent oxidoreductases has shown that the relative orientation of the nicotinamide ring, its associated ribose, and the enzyme active site are often closely related. Moreover, the catalytic oxidation-reduction cycle in these enzymes necessarily leads to a situation where the electron system of a substrate approaches the face of the nicotinamide ring. Thus, for the subset of dehydrogenases where there is sufficient space in the structure around the 2ЈOH group of the nicotinamide ribose, there is an excellent opportunity to mimic the chemistry seen in the NAD ϩ -diazaborine complex in the synthesis of new enzyme inhibitors. For example, the superposition of the nucleotide-inhibitor complex of ENR into the active site of the nucleotide-substrate complex of DHFR indicates that linking a folate analog to the nicotinamide ribose is a distinct possibility, and such a strategy might be used in the design of new anticancer agents (Fig. 1D) . Moreover, the similarity between the ENR-NAD ϩ -diazaborine complex and the orientation of the inosine-5Ј-monophosphate thioimidate intermediate and the inhibitor MPA in IMPDH (15) suggests that the 2Ј hydroxyl of the inosine might be linked to the inhibitor in a similar manner; however, coordinates of the latter are not yet available for a more detailed comparison. These examples suggest that the use of the ribose hydroxyl to create a bisubstrate analog may find important applications in other areas of medicinal chemistry. [Produced using LIGPLOT (28) .]
